Tamari Keisuke, Konno Masamitsu, Asai Ayumu, Koseki Jun, Hayashi Kazuhiko, Kawamoto Koichi, Murai Noriyuki, Matsufuji Senya, Isohashi Fumiaki, Satoh Taroh, Goto Noriko, Tanaka Shinji, Doki Yuichiro, Mori Masaki, Ogawa Kazuhiko, Ishii Hideshi
1Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871 Japan.
2Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565-0871 Japan.
Cell Death Discov. 2018 Nov 13;4:104. doi: 10.1038/s41420-018-0117-7. eCollection 2018.
Cancer stem cells (CSCs) exhibit tumorigenic potential and can generate resistance to chemotherapy and radiotherapy. A labeled ornithine decarboxylase (ODC, a rate-limiting enzyme involved in polyamine [PA] biosynthesis) degradation motif (degron) system allows visualization of a fraction of CSC-like cells in heterogeneous tumor populations. A labeled ODC degradation motif system allowed visualization of a fraction of CSC-like cells in heterogeneous tumor populations. Using this system, analysis of polyamine flux indicated that polyamine metabolism is active in CSCs. The results showed that intracellular polyamines inhibited the activity of histone lysine 4 demethylase enzymes, including lysine-specific demethylase-1 (LSD1). Chromatin immunoprecipitation with Pol II antibody followed by massively parallel DNA sequencing, revealed the global enrichment of Pol II in transcription start sites in CSCs. Increase of polyamines within cells resulted in an enhancement of ID1 gene expression. The results of this study reveal details of metabolic pathways that drive epigenetic control of cancer cell stemness and determine effective therapeutic targets in CSCs.
癌症干细胞(CSCs)具有致瘤潜力,并且能够产生对化疗和放疗的抗性。一种标记的鸟氨酸脱羧酶(ODC,一种参与多胺[PA]生物合成的限速酶)降解基序(degron)系统能够使异质性肿瘤群体中的一部分类CSC细胞可视化。一种标记的ODC降解基序系统能够使异质性肿瘤群体中的一部分类CSC细胞可视化。利用该系统,对多胺通量的分析表明多胺代谢在CSCs中是活跃的。结果显示,细胞内多胺抑制了包括赖氨酸特异性去甲基化酶-1(LSD1)在内的组蛋白赖氨酸4去甲基化酶的活性。用Pol II抗体进行染色质免疫沉淀,随后进行大规模平行DNA测序,揭示了Pol II在CSCs转录起始位点的整体富集。细胞内多胺的增加导致ID1基因表达增强。这项研究的结果揭示了驱动癌细胞干性表观遗传控制并确定CSCs中有效治疗靶点的代谢途径的细节。